David A. Hollander
2019
In 2019, David A. Hollander earned a total compensation of $2.1M as Chief Research and Development Officer at Aerie Pharmaceuticals.
Compensation breakdown
| Non-Equity Incentive Plan | $185,000 |
|---|---|
| Option Awards | $1,371,985 |
| Salary | $61,894 |
| Stock Awards | $476,250 |
| Total | $2,095,129 |
Hollander received $1.4M in option awards, accounting for 65% of the total pay in 2019.
Hollander also received $185K in non-equity incentive plan, $61.9K in salary and $476.3K in stock awards.
Rankings
In 2019, David A. Hollander's compensation ranked 5,689th out of 13,971 executives tracked by ExecPay. In other words, Hollander earned more than 59.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,689 out of 13,971 | 59th |
Division Manufacturing | 2,126 out of 5,701 | 63rd |
Major group Chemicals And Allied Products | 761 out of 2,200 | 65th |
Industry group Drugs | 639 out of 1,886 | 66th |
Industry Biological Products, Except Diagnostic Substances | 154 out of 389 | 60th |
Source: SEC filing on April 27, 2021.
Hollander's colleagues
We found five more compensation records of executives who worked with David A. Hollander at Aerie Pharmaceuticals in 2019.
2019
Vicente Anido
Aerie Pharmaceuticals
Chief Executive Officer
2019
Thomas Mitro
Aerie Pharmaceuticals
Chief Operating Officer
2019
John LaRocca
Aerie Pharmaceuticals
General Counsel
2019
Richard Rubino
Aerie Pharmaceuticals
Chief Financial Officer
2019
Casey Kopczynski
Aerie Pharmaceuticals